On May 19, 2025, B of A Securities analyst Tazeen Ahmad maintained the rating on Sutro Biopharma (STRO, Financial) as "Underperform." This rating remains unchanged from the previous assessment.
In addition to reaffirming the underperform rating, the analyst has also lowered the price target for Sutro Biopharma (STRO, Financial). The new price target is set at USD 0.80, down from the previous target of USD 1.00, reflecting a decrease of 20%.
Sutro Biopharma (STRO, Financial), listed on the NASDAQ, continues to face challenges, as indicated by the sustained "Underperform" rating and the adjusted price target. Investors and market watchers should take note of these updates when considering their positions in Sutro Biopharma (STRO).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Sutro Biopharma Inc (STRO, Financial) is $4.10 with a high estimate of $10.00 and a low estimate of $0.80. The average target implies an upside of 373.22% from the current price of $0.87. More detailed estimate data can be found on the Sutro Biopharma Inc (STRO) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Sutro Biopharma Inc's (STRO, Financial) average brokerage recommendation is currently 2.6, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sutro Biopharma Inc (STRO, Financial) in one year is $1.90, suggesting a upside of 119.3% from the current price of $0.8664. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sutro Biopharma Inc (STRO) Summary page.
